Limited impact of the COVID-19 pandemic on colorectal cancer care in the Netherlands in 2020

• Published in: International journal of colorectal disease 2022-09, Vol.37 (9), p.2013-2020
• Main Authors: Meijer, Joyce, Elferink, Marloes A. G., Vink, Geraldine R., Sijtsma, Femke P. C., Buijsen, Jeroen, Nagtegaal, Iris D., Tanis, Pieter J., Wumkes, Miriam L., de Hingh, Ignace H. J. T., Siesling, Sabine
• Format: Article
• Language: English
• Subjects: Adjuvant treatment; Cancer; Care and treatment; Colon cancer; Colorectal cancer; Colorectal carcinoma; Coronaviruses; COVID-19; Diagnosis; Gastroenterology; Hepatology; Internal Medicine; Long-term effects; Medicine; Medicine & Public Health; Pandemics; Patients; Proctology; Radiation therapy; Surgery
• ISSN: 1432-1262; 0179-1958; 1432-1262
• DOI: 10.1007/s00384-022-04209-4

Purpose The COVID-19 pandemic had a major impact on the health services worldwide. We aimed to investigate the impact of the pandemic on colorectal cancer (CRC) care in the Netherlands in 2020. Methods CRC patients, diagnosed in 2018–2020 in the Netherlands, were selected from the Netherlands Cancer Registry (NCR). The year 2020 was divided in four periods reflecting COVID-19 developments in the Netherlands (pre-COVID, 1st peak, recovery period, 2nd peak) and compared with the same periods in 2018/2019. Patient characteristics and treatment were compared using the Chi-squared test. Median time between diagnosis and treatment, and between (neo)adjuvant therapy and surgery were analyzed by the Mann–Whitney U test. Results In total, 38,021 CRC patients were diagnosed in 2018/2019 ( n  = 26,816) and 2020 ( n  = 11,205). Median time between diagnosis and initial treatment decreased on average 4 days and median time between neoadjuvant radiotherapy and surgery in clinical stage II or III rectal cancer patients increased on average 34 days during the three COVID-19 periods compared to the same periods of 2018/2019. The proportion of colon cancer patients that underwent elective surgery significantly decreased with 3.0% during the 1st peak. No differences were found in the proportion of patients who received (neo)adjuvant therapy, systemic therapy, or no anti-cancer treatment. Conclusion Only minor changes in the care for CRC patients occurred during the COVID-19 pandemic, mostly during the 1 st peak. In conclusion, the impact on CRC care in the Netherlands was found to be limited. However, long-term effects cannot be precluded.